Breastfeeding is closely associated with the health of the mother and child. In fact, particularly since this depends on the exclusivity of breastfeeding (thus, from the fact that no other foods are added to the child’s date) and its duration.
The more exclusive and prolonged breastfeeding is, the greater the investment in terms of health for the child and the mother. The World Health Organization recommendations (WHO) are based on these recommendations to exclusively breastfeeding through the first six months of the child’s life and to continue even after weaning.
Despite this, from time to time, there have been numerous contraindications to breastfeeding in the past, many of which were associated with diseases and the use of drugs. The intake of a drug by the nursing mother should only be deemed incompatible when there are reasonable grounds to do so.
Yet, the safety assessment of the use of a drug during nursing is different depending on the international agencies (such as WHO or UNICEF) or the scientific companies that deal with health.
These recommendations are often discordant because they depend on different the analyses and evaluations of the limited data available on pharmacokinetics in lactating women and side effects on the nursing infant reported in the literature, with the tendency to overestimate the risk associated with the presence of a drug in breast milk.
It is curious that, according to the drug information leaflets ( “leaflets”) found in pharmaceutical product packaging, approximately 80% of the over 11 thousand drugs available on the Italian market is contraindicated during nursing, while only 2% of drugs have been clearly deemed safe. Consequently, this data affect the decisions of health workers, said users.